CymaBay Therapeutics ROA 2013-2019 | CBAY

Current and historical return on assets (ROA) values for CymaBay Therapeutics (CBAY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. CymaBay Therapeutics ROA for the three months ending June 30, 2019 was -37.09%.
CymaBay Therapeutics ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2019-06-30 $-0.09B $0.25B -37.04%
2019-03-31 $-0.08B $0.27B -35.79%
2018-12-31 $-0.07B $0.19B -34.72%
2018-09-30 $-0.06B $0.20B -31.13%
2018-06-30 $-0.05B $0.22B -29.18%
2018-03-31 $-0.04B $0.23B -33.99%
2017-12-31 $-0.03B $0.10B -42.86%
2017-09-30 $-0.03B $0.10B -69.46%
2017-06-30 $-0.03B $0.02B -122.73%
2017-03-31 $-0.03B $0.03B -101.01%
2016-12-31 $-0.03B $0.02B -97.30%
2016-09-30 $-0.03B $0.03B -77.04%
2016-06-30 $-0.03B $0.03B -65.41%
2016-03-31 $-0.02B $0.04B -50.63%
2015-12-31 $-0.02B $0.04B -38.46%
2015-09-30 $-0.02B $0.05B -58.67%
2015-06-30 $-0.02B $0.03B -60.27%
2015-03-31 $-0.02B $0.04B -67.13%
2014-12-31 $-0.03B $0.04B -92.09%
2014-09-30 $0.19B $0.05B 571.85%
2014-06-30 $0.24B $0.03B 793.44%
2014-03-31 $0.24B $0.03B 1000.00%
2013-12-31 $0.24B $0.03B 1501.54%
2013-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.395B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.499B 9.94
Mylan (MYL) United Kingdom $11.189B 4.93
Teva Pharmaceutical Industries (TEVA) Israel $8.670B 3.41
Bausch Health Cos (BHC) Canada $8.178B 5.46
Dr Reddy's Laboratories (RDY) India $6.439B 21.67
ASPEN PHARMACR (APNHY) South Africa $2.928B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.444B 14.12
Amphastar Pharmaceuticals (AMPH) United States $1.016B 50.05
Homology Medicines (FIXX) United States $0.906B 0.00
Voyager Therapeutics (VYGR) United States $0.635B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.462B 0.00
Akorn (AKRX) United States $0.458B 0.00
Assembly Biosciences (ASMB) United States $0.292B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.283B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.277B 0.38
Adamas Pharmaceuticals (ADMS) United States $0.176B 0.00
Sol-Gel Technologies (SLGL) Israel $0.163B 0.00
Teligent (TLGT) United States $0.054B 0.00